Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

73.3%

11 terminated/withdrawn out of 15 trials

Success Rate

21.4%

-65.1% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results7 withdrawn

Enrollment Performance

Analytics

Phase 2

6(40.0%)

Phase 1

6(40.0%)

Phase 3

2(13.3%)

N/A

1(6.7%)

15Total

Phase 2(6)

Phase 1(6)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05325281Phase 1Terminated

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Role: collaborator

NCT03374852Phase 2Withdrawn

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Role: collaborator

NCT05854966Phase 2Withdrawn

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Role: collaborator

NCT06518538Phase 2Withdrawn

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

Role: lead

NCT05070104Phase 1Withdrawn

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Role: lead

NCT04593758Phase 1Completed

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Role: lead

NCT03504410Phase 3Terminated

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Role: lead

NCT03504423Phase 3Completed

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Role: lead

NCT03435289Phase 1Unknown

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Role: collaborator

NCT00907166Phase 1Terminated

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Role: lead

NCT01832857Phase 2Terminated

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Role: lead

NCT01520805Phase 2Withdrawn

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Role: lead

NCT00741403Phase 1Completed

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Role: lead

NCT01537354Not ApplicableWithdrawn

Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

Role: collaborator

NCT01830322Phase 2Withdrawn

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Role: lead

All 15 trials loaded